2024
Development and comparison of immunologic assays to detect primary RSV infections in infants
Anderson L, Jadhao S, Hussaini L, Ha B, McCracken C, Gibson T, Yildirim I, Yi J, Stephens K, Korski C, Kao C, Sun H, Lee C, Jaunarajs A, Rostad C, Anderson E. Development and comparison of immunologic assays to detect primary RSV infections in infants. Frontiers In Immunology 2024, 14: 1332772. PMID: 38283339, PMCID: PMC10811012, DOI: 10.3389/fimmu.2023.1332772.Peer-Reviewed Original ResearchConceptsRespiratory syncytial virusIgG enzyme immunoassayNeutralizing antibody assaysELISPOT assayAntibody assayRSV antibodiesEnzyme immunoassayRSV infectionSubgroup ARespiratory syncytial virus seasonDocumented RSV infectionPrimary RSV infectionEffective respiratory syncytial virusVaccine clinical trialsEvidence of past infectionEpidemiological studiesRed cell lysisYoung childrenMaternal microchimerismPBMC specimensPregnant womenIFN-gSyncytial virusAntibody enzyme immunoassayELISPOT
2023
Age-dependent impairment in antibody responses elicited by a homologous CoronaVac booster dose
Filardi B, Monteiro V, Schwartzmann P, do Prado Martins V, Zucca L, Baiocchi G, Malik A, Silva J, Hahn A, Chen N, Pham K, Pérez-Then E, Miric M, Brache V, Cochon L, Larocca R, Della Rosa Mendez R, Silveira D, Pinto A, Croda J, Yildirim I, Omer S, Ko A, Vermund S, Grubaugh N, Iwasaki A, Lucas C, Initiative Y, Vogels C, Breban M, Koch T, Chaguza C, Tikhonova I, Castaldi C, Mane S, De Kumar B, Ferguson D, Kerantzas N, Peaper D, Landry M, Schulz W. Age-dependent impairment in antibody responses elicited by a homologous CoronaVac booster dose. Science Translational Medicine 2023, 15: eade6023. PMID: 36791210, DOI: 10.1126/scitranslmed.ade6023.Peer-Reviewed Original ResearchConceptsBooster doseAntibody responseNeutralization titersVirus-specific IgG titersOlder adultsAntiviral humoral immunityPlasma antibody responsesHigh-risk populationSARS-CoV-2 spikeYears of ageAge-dependent impairmentHeterologous regimensBooster dosesBooster vaccineCoronaVac vaccineIgG titersProtective immunityHumoral immunityHumoral responseCoronaVacOmicron waveBooster strategyAge groupsEarly controlVaccine
2021
COVID-19 Vaccine Uptake Among US Child Care Providers
Patel KM, Malik AA, Lee A, Klotz M, Humphries JE, Murray T, Wilkinson D, Shafiq M, Yildirim I, Elharake JA, Diaz R, Reyes C, Omer SB, Gilliam WS. COVID-19 Vaccine Uptake Among US Child Care Providers. Pediatrics 2021, 148: e2021053813. PMID: 34452977, PMCID: PMC9277775, DOI: 10.1542/peds.2021-053813.Peer-Reviewed Original ResearchConceptsCOVID-19 vaccine uptakeVaccine uptakeCare providersChild care providersVaccination ratesSevere acute respiratory syndrome coronavirus 2Adult populationState public health leadersUS general adult populationAcute respiratory syndrome coronavirus 2General US adult populationRespiratory syndrome coronavirus 2Home-based child care programsSyndrome coronavirus 2US adult populationGeneral adult populationCross-sectional surveyPublic health implicationsPublic health leadersAnnual household incomeCoronavirus 2Care settingsInclusion criteriaCare programChild care settingsImpact of circulating SARS-CoV-2 variants on mRNA vaccine-induced immunity
Lucas C, Vogels CBF, Yildirim I, Rothman JE, Lu P, Monteiro V, Gehlhausen JR, Campbell M, Silva J, Tabachnikova A, Peña-Hernandez MA, Muenker MC, Breban MI, Fauver JR, Mohanty S, Huang J, Shaw A, Ko A, Omer S, Grubaugh N, Iwasaki A. Impact of circulating SARS-CoV-2 variants on mRNA vaccine-induced immunity. Nature 2021, 600: 523-529. PMID: 34634791, PMCID: PMC9348899, DOI: 10.1038/s41586-021-04085-y.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 variantsMRNA vaccine-induced immunityT-cell activation markersSARS-CoV-2 antibodiesSecond vaccine doseVaccine-induced immunityCell activation markersT cell responsesHigh antibody titresSARS-CoV-2Vaccine boosterVaccine doseActivation markersVaccine dosesHumoral immunityAntibody titresMRNA vaccinesVitro stimulationNeutralization capacityNeutralization responseCell responsesE484KNucleocapsid peptideAntibody-binding sitesGreater reductionDelayed production of neutralizing antibodies correlates with fatal COVID-19
Lucas C, Klein J, Sundaram ME, Liu F, Wong P, Silva J, Mao T, Oh JE, Mohanty S, Huang J, Tokuyama M, Lu P, Venkataraman A, Park A, Israelow B, Vogels CBF, Muenker MC, Chang CH, Casanovas-Massana A, Moore AJ, Zell J, Fournier JB, Wyllie A, Campbell M, Lee A, Chun H, Grubaugh N, Schulz W, Farhadian S, Dela Cruz C, Ring A, Shaw A, Wisnewski A, Yildirim I, Ko A, Omer S, Iwasaki A. Delayed production of neutralizing antibodies correlates with fatal COVID-19. Nature Medicine 2021, 27: 1178-1186. PMID: 33953384, PMCID: PMC8785364, DOI: 10.1038/s41591-021-01355-0.Peer-Reviewed Original ResearchConceptsDeceased patientsAntibody levelsAntibody responseDisease severityAnti-S IgG levelsCOVID-19 disease outcomesFatal COVID-19Impaired viral controlWorse clinical progressionWorse disease severitySevere COVID-19Length of hospitalizationImmunoglobulin G levelsHumoral immune responseCoronavirus disease 2019COVID-19 mortalityCOVID-19Domain (RBD) IgGSeroconversion kineticsDisease courseIgG levelsClinical parametersClinical progressionHumoral responseDisease onset
2020
Differences in maternal group B Streptococcus screening rates in Latin American countries
HogenEsch E, De Mucio B, Haddad LB, Vilajeliu A, Ropero AM, Yildirim I, Omer SB. Differences in maternal group B Streptococcus screening rates in Latin American countries. Vaccine 2020, 39: b3-b11. PMID: 33308886, DOI: 10.1016/j.vaccine.2020.10.082.Peer-Reviewed Original ResearchConceptsMaternal GBS screeningMaternal GBS colonizationGBS screeningGBS colonizationScreening ratesPregnant womenGroup B Streptococcus ScreeningMaternal group B StreptococcusLogistic regressionGBS colonization prevalenceIntrapartum antibiotic treatmentMaternal GBS vaccineNeonatal GBS diseaseAdverse neonatal outcomesRetrospective observational studyMaternal age groupsGroup B streptococciDemographic variablesLower ratesGBS prevalenceFinal regression modelGBS diseaseNeonatal outcomesNeonatal sepsisGBS vaccine
2015
Pneumococcal Disease in the Era of Pneumococcal Conjugate Vaccine
Yildirim I, Shea KM, Pelton SI. Pneumococcal Disease in the Era of Pneumococcal Conjugate Vaccine. Infectious Disease Clinics Of North America 2015, 29: 679-697. PMID: 26610421, PMCID: PMC4662776, DOI: 10.1016/j.idc.2015.07.009.Peer-Reviewed Original ResearchConceptsPneumococcal conjugate vaccinePneumococcal diseaseConjugate vaccineOtitis mediaUniversal immunizationAcute otitis mediaInvasive pneumococcal diseaseCase fatality rateVulnerable pediatric patientsSpectrum of serotypesCause pneumoniaPediatric patientsComorbid conditionsHealthy childrenFatality rateDiseaseHost susceptibilityImmunizationVaccineHigh rateChildrenEmpyemaMastoiditisPneumoniaPatients
2010
Serosurveillance study on transmission of H5N1 virus during a 2006 avian influenza epidemic
CEYHAN M, YILDIRIM I, FERRARIS O, BOUSCAMBERT-DUCHAMP M, FROBERT E, UYAR N, TEZER H, ONER AF, BUZGAN T, TORUNOGLU MA, OZKAN B, YILMAZ R, KURTOGLU MG, LALELI Y, BADUR S, LINA B. Serosurveillance study on transmission of H5N1 virus during a 2006 avian influenza epidemic. Epidemiology And Infection 2010, 138: 1274-1280. PMID: 20092669, DOI: 10.1017/s095026880999166x.Peer-Reviewed Original ResearchConceptsSerum samplesSubclinical infectionAvian influenza patientsSingle serum sampleAvian influenzaEnzyme-linked immunoassayPoultry cullersInfluenza patientsMicroneutralization assaysNasopharyngeal swabsPolymerase chain reactionSerosurveillance studiesH5N1 infectionHealthcare workersHaemagglutination inhibitionInfluenza epidemicsHuman infectionsSerological surveyFamily contactsHuman casesH5N1 virusInfectionDiseased poultryInfected chickensChain reaction
2008
Differences in hepatitis A seroprevalence among geographical regions in Turkey: a need for regional vaccination recommendations
Ceyhan M, Yildirim I, Kurt N, Uysal G, Dikici B, Ecevit C, Aydogan A, Koc A, Yasa O, Köseoğlu M, Onal K, Hacimustafaoglu M, Celebi S. Differences in hepatitis A seroprevalence among geographical regions in Turkey: a need for regional vaccination recommendations. Journal Of Viral Hepatitis 2008, 15: 69-72. PMID: 18837839, DOI: 10.1111/j.1365-2893.2008.01034.x.Peer-Reviewed Original ResearchConceptsRecommendation of vaccinationAnti-HAV antibodiesVaccine-preventable infectionsImmunoglobulin G antibodiesYears of ageLow endemicity regionsEnzyme-linked immunosorbentWorld Health OrganizationUniversal hepatitisIntermediate endemicityVaccination recommendationsHepatitis AOverall prevalenceVaccination policyMedical CenterMass vaccinationImmunization policyAge groupsVaccinationHealth OrganizationSocioeconomic differencesHepatitisEndemicityHygiene conditionsAge
2007
Age-specific seroprevalence of serogroup C meningococcal serum bactericidal antibody activity and serogroup A, C, W135 and Y-specific IgG concentrations in the Turkish population during 2005
Ceyhan M, Yildirim I, Balmer P, Riley C, Laher G, Andrews N, Borrow R, Kurt N, Turgut M, Aydogan A, Ecevit C, Uysal G, Schultze V. Age-specific seroprevalence of serogroup C meningococcal serum bactericidal antibody activity and serogroup A, C, W135 and Y-specific IgG concentrations in the Turkish population during 2005. Vaccine 2007, 25: 7233-7237. PMID: 17707957, DOI: 10.1016/j.vaccine.2007.07.019.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAge FactorsAgedAged, 80 and overAntibodies, BacterialChildChild, PreschoolFemaleHumansImmunoglobulin GInfantInfant, NewbornMaleMeningococcal InfectionsMicrobial ViabilityMiddle AgedNeisseria meningitidis, Serogroup ANeisseria meningitidis, Serogroup CNeisseria meningitidis, Serogroup W-135Neisseria meningitidis, Serogroup YSeroepidemiologic StudiesTurkeyConceptsSerum bactericidal antibodySerogroups ASerogroup CIgG concentrationsMeningococcal serogroup C diseaseSerum bactericidal antibody activityTurkish populationMeningococcal serogroup CMeningococcal vaccination programsSerogroup C diseaseAge-specific seroprevalenceSpecific IgG concentrationsRates of susceptibilityBactericidal antibody activityBaseline seroprevalenceSBA titersAntibody levelsProtective antibodiesIgG antibodiesVaccination programBactericidal antibodiesHealth centersC diseaseStudy populationC meningococci